Eli Lilly to purchase Loxo Oncology for $8bn
07-01-2019
AbbVie in immuno-oncology agreement with biotech
23-08-2018
Eli Lilly to buy immuno-oncology firm in $1.6bn deal
11-05-2018
NicoElnino / iStockphoto.com
Eli Lilly has revealed plans to acquire Montreal-based AurKa Pharma, in what is the company’s second acquisition in less than one week.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Eli Lilly, mergers & acquisitions, M&A, AurKa Pharma, oncology, TVM Capital Life Science, cancer drug, cells, cancer
